Start of procedure: Type II Variation - Extension of indication under evaluation by the CHMP (12 December 2025 - 29 January 2026)
Human medicines European public assessment report (EPAR): Kirsty (previously Kixelle), insulin aspart, Date of authorisation: 05/02/2021, Revision: 5, Status: Authorised
Human medicines European public assessment report (EPAR): Sugammadex Amomed, sugammadex, Date of authorisation: 10/01/2023, Revision: 5, Status: Authorised
Epidemiological data on blood transmissible infections - Scientific guideline
Committee for Advanced Therapies (CAT): Work Plan 2026
Interested Parties to the HMPC
Hearing the Association of the European Self-Medication Industry (AESGP) during the HMPC November 2025 meeting
PRAC rapporteur post-authorisation-safety-study-protocol assessment-report template
Template PRAC assessment report of an non-interventional imposed PASS final study report
Human medicines European public assessment report (EPAR): Leqembi, lecanemab, Date of authorisation: 15/04/2025, Revision: 2, Status: Authorised